Brief: Eiger Biopharmaceuticals Reports Fourth Quarter And Full Year 2021 Financial Results
10/03/2022 21:02
March 10 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL
YEAR
2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* CASH, CASH EQUIVALENTS AND INVESTMENTS OF $106.1 MILLION
TO
BEGIN 2022 EXPECTED TO FUND PLANNED OPERATIONS THROUGH Q3 2023
* Q4 LOSS PER SHARE $0.64
Source text for Eikon: ID:nPn3PbrwLa
Further company coverage: EIGR.O
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview